Abstract
Introduction Psoriasis (PsO), psoriatic arthritis (PsA) and inflammatory bowel disease (IBD), i.e. Crohn’s disease (CD) and ulcerative colitis (UC) are chronic systemic immune-mediated disorders affecting an increasing proportion of adults and children worldwide. Observational studies suggested an association between IBD and PsO and vice versa. However, so far it remains unclear whether a causal relationship exists.
Methods To investigate the causal paths, a bidirectional two-sample Mendelian randomization (MR) study was conducted using summary statistics from genome-wide association studies (GWASs) including up to 463,372 Europeans. Total and direct effects were derived performing an iterative radial and robust inverse-variance weighted method within the univariable and multivariable MR setting, respectively. Causal estimates were verified using a validation IBD-sample, a series of pleiotropy-robust MR-methods, and sensitivity analyses based on PhenoScanner search in conjunction with network analysis.
Results Genetically predicted IBD was associated with higher risk of PsO (pooled OR=1.10; 95% CI: (1.05; 1.15); P=1⋅10−4) and PsA (pooled OR=1.10; 95% CI: (1.04; 1.18); P=3⋅10−3). In contrast to UC, the CD subentity was related to PsO (OR=1.16; 95% CI: (1.12; 1.20); P=1⋅10−14) and PsA (OR=1.13; 95% CI: (1.06; 1.20); P=1⋅10−4). Regarding the reverse directions, no notable associations could be found.
Conclusions This study supports a causal effect between IBD and PsO as well as PsA, but not vice versa. It seems that mainly CD and not UC is responsible for the causal impact of IBD on both psoriasis outcomes. These findings have implications for the management of IBD and psoriasis in clinical practice.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The authors did not receive funding for this study. Funding information of the genome-wide association studies is specified in the cited studies.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Summary level data for the IBD-discovery (including CD and UC) and IBD-validation samples are freely available from the International Inflammatory Bowel Disease Genetics Consortium and cnsgenomics, respectively. Instructions for downloading the PsO and PsA data can be found at the FinnGen consortium.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
Summary level data for the IBD-discovery (including CD and UC) and IBD-validation samples are freely available from the International Inflammatory Bowel Disease Genetics Consortium (https://www.ibdgenetics.org/downloads.html) and cnsgenomics (https://cnsgenomics.com/content/data), respectively. Instructions for downloading the PsO and PsA data can be found at the FinnGen consortium (https://www.finngen.fi/en/access_results).
https://www.ibdgenetics.org/downloads.html
Abbreviations
- CI
- Confidence Interval
- GWAS
- Genome-Wide Association Study
- IBD
- Inflammatory Bowel Disease
- IVW
- Inverse-Variance Weighted
- MR
- Mendelian Randomization
- OR
- Odds Ratio
- PsA
- Psoriatic Arthritis
- PsO
- Psoriasis
- SNP
- Single Nucleotide Polymorphism